Uses
QULIPTA is indicated for the preventive treatment of migraine in adults. QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.
Source: US FDA prescribing information
Molecule
Atogepant
Calcitonin Gene-related Peptide Receptor Antagonist
Available on requestPain and anaesthesia
- Presentations
- 3
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Atogepant is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. It is available as tablets for oral use. MedsAcross supplies Atogepant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Calcitonin Gene-related Peptide Receptor Antagonist, Calcitonin Gene-related Peptide Receptor Antagonists
- ATC classification
- N02CD07 Atogepant · Antimigraine, subgroup N02CD
- US FDA first approval
- 28 September 2021
- EU status
- Authorised
- Orphan designation
- No
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral
- Dosage forms
- Tablet
- Identifiers
- UNII 7CRV8RR151CAS 1374248-81-3DrugBank DB16098Q76797798
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Source: US FDA prescribing information
Dosing overview
QULIPTA is taken orally with or without food. For episodic migraine, the recommended dosage is 10 mg, 30 mg, or 60 mg taken once daily. For chronic migraine, the recommended dosage is 60 mg taken once daily. Severe Renal Impairment or End-Stage Renal Disease: Episodic migraine: 10 mg once daily. Chronic migraine: Not recommended.
Source: US FDA prescribing information
Contraindications
QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA. Reactions have included anaphylaxis and dyspnea. Patients with a history of hypersensitivity to atogepant or to any of the components of QULIPTA.
Source: US FDA prescribing information
Warnings and precautions
Hypersensitivity Reactions: If a hypersensitivity reaction occurs, discontinue QULIPTA and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis and dyspnea. These reactions can occur days after administration. Hypertension: New-onset or worsening of pre-existing hypertension may occur. Raynaud’s phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur.
Source: US FDA prescribing information
Side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Hypertension Raynaud’s Phenomenon The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.
Source: US FDA prescribing information
Interactions
Recommended dosage modifications: Strong CYP3A4 Inhibitors: Episodic or chronic migraine: 10 mg once daily Strong CYP3A4 Inducers: Episodic migraine: 60 mg once daily (monitor for reduced efficacy). Chronic migraine: Not recommended. Moderate CYP3A4 Inducers: Episodic migraine: 60 mg once daily. Weak CYP3A4 Inducers: Episodic migraine: 30 mg or 60 mg once daily. Chronic migraine: 60 mg once daily. OATP Inhibitors: Episodic migraine: 10 mg or 30 mg once daily. Chronic migraine: 30 mg once daily.
Source: US FDA prescribing information
Storage
Store between 20°C and 25°C (68°F and 77°F): excursions permitted between 15°C and 30°C (59°F and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
3 presentations of Atogepant, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Qulipta 10 mg tabletOral | AbbVie | US FDA | Available on request |
| Qulipta 30 mg tabletOral | AbbVie | US FDA | Available on request |
| Qulipta 60 mg tabletOral | AbbVie | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Questions and answers
Is Atogepant available for export from India?
Yes, on request. MedsAcross lists 3 presentations of Atogepant and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Atogepant have?
The catalogue lists 1 brand names for Atogepant, including Qulipta.
Is Atogepant approved by the US FDA?
Yes. The US FDA first approved Atogepant on 28 September 2021, according to Drugs@FDA.
Is Atogepant authorised in the European Union?
Yes. Atogepant has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
Does Atogepant need cold chain shipping?
No listed presentation of Atogepant is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Atogepant in?
Atogepant is classified under ATC code N02CD07 (Atogepant).
References
- Qulipta prescribing information (AbbVie). U.S. National Library of Medicine, DailyMed. Retrieved 30 September 2025
- Aquipta: European public assessment report (EPAR). European Medicines Agency. Retrieved 25 August 2026
Request Atogepant for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.